XTL Biopharmaceuticals (NASDAQ: XTLB) — Perfil da empresa, notícias e dados financeiros
XTL Biopharmaceuticals develops treatments for autoimmune diseases, focusing on innovative therapies and addressing unmet medical needs.
XTL Biopharmaceuticals
XTL Biopharmaceuticals ADR (TLV:XTLB), (NASDAQ:XTLB) focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of autoimmune diseases. Their project pipeline mainly includes therapies aimed at conditions like systemic lupus erythematosus and multiple myeloma, showcasing a commitment to addressing hard-to-treat autoimmune disorders. The company's objectives are centered on advancing these projects through clinical trials towards regulatory approval, striving to meet unmet medical needs within these therapeutic areas. Their operations span from research and development to strategic partnerships aimed at enhancing their product portfolio and expanding their reach in the biopharmaceutical market.
Resumo
Operações
Produtos e/ou serviços de XTL Biopharmaceuticals
- Development of hCDR1 (edratide) for the treatment of systemic lupus erythematosus, a potential therapy aimed at reducing symptoms and disease progression.
- Research into therapies for multiple myeloma, focusing on small molecule drugs targeting specific pathways involved in the disease's progression.
- Advancement of potential treatments for hepatitis C, through the exploration of novel antiviral compounds that could inhibit the virus's ability to replicate.
- Investigation into autoimmune diseases, aiming to identify new therapeutic targets and develop innovative drugs to modulate the immune system.
- Conducting clinical trials for advanced drug candidates in inflammatory diseases, with a focus on achieving significant improvements in patient outcomes and quality of life.
- Collaboration with leading pharmaceutical companies and academic institutions to leverage cutting-edge research and development capabilities, enhancing the pipeline of therapies in various stages of development.
equipe executiva do XTL Biopharmaceuticals
- Noam BandCEO & Director
- Segal NivChief Financial Officer
Principais indicadores financeiros
Resultados divulgados pela XTL Biopharmaceuticals , em USD.
- Cap. de mercado
- 4,4 mi
- Receita (TTM)
- 968 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -1,7 mi | -7 mi | |
| 451 mil | -2,2 mi | -1 mi | |
| 0 | -765 mil | -1,8 mil | |
| -459 mil | -880 mil | -1,3 mi |